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ABSTRACT
Previous studies have demonstrated focal but limited molecular similarities 
between circulating tumor cells (CTCs) and biopsies using isolated genetic assays. We 
hypothesized that molecular similarity between CTCs and tissue exists at the single 
cell level when characterized by whole genome sequencing (WGS). By combining the 
NanoVelcro CTC Chip with laser capture microdissection (LCM), we developed a platform 
for single-CTC WGS. We performed this procedure on CTCs and tissue samples from a 
patient with advanced prostate cancer who had serial biopsies over the course of his 
clinical history. We achieved 30X depth and ≥ 95% coverage. Twenty-nine percent of 
the somatic single nucleotide variations (SSNVs) identified were founder mutations 
that were also identified in CTCs. In addition, 86% of the clonal mutations identified in 
CTCs could be traced back to either the primary or metastatic tumors. In this patient, 
we identified structural variations (SVs) including an intrachromosomal rearrangement 
in chr3 and an interchromosomal rearrangement between chr13 and chr15. These 
rearrangements were shared between tumor tissues and CTCs. At the same time, highly 
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heterogeneous short structural variants were discovered in PTEN, RB1, and BRCA2 in 
all tumor and CTC samples. Using high-quality WGS on single-CTCs, we identified the 
shared genomic alterations between CTCs and tumor tissues. This approach yielded 
insight into the heterogeneity of the mutational landscape of SSNVs and SVs. It may 
be possible to use this approach to study heterogeneity and characterize the biological 
evolution of a cancer during the course of its natural history.
INTRODUCTION
Circulating tumor cells (CTCs) are rare cancer cells 
within the circulation in patients with an underlying solid 
tumor malignancy [1]. We and other have postulated that 
they play a role in the process of metastases [2] and, as 
such, may be an alternative source of tissue for molecular 
study- i.e. a “liquid biopsy”. Such an approach would 
confer an important advantage over conventional tissue 
biopsy: characterization of the dynamic biology of a cancer. 
Detection and characterization of CTCs has been technically 
challenging due to their extremely low relative abundance 
in the bloodstream [3, 4]. Many assays [5–13] efficiently 
capture CTCs, but do not provide cells appropriate for 
contemporary molecular analyses such as whole genome 
sequencing (WGS).
Several studies have shown similarities between 
CTCs and tumor tissues using targeted sequencing 
approaches [14–16] and copy number analysis [17]. Our 
group and others have performed whole exome sequencing 
(WES) on CTCs [18–20]. While an important advance, 
the coverage of the sequencing (43–71%) could still be 
improved. In addition, WES has its intrinsic limitations 
to identify genome rearrangements, which are now 
recognized as important in prostate cancer (PCa) [21].
With advances in single-cell sequencing [22, 23] and 
single-CTC isolation technologies [15, 18], our group set out 
to compare single-CTCs and tumor biopsies using WGS. We 
demonstrated that high quality WGS can be done utilizing 
these single-CTCs. This improved quality in sequencing 
allowed us to test the hypothesis that CTCs and tumor tissues 
have shared somatic single nucleotide variations (SSNVs) 
and rearrangements due to their shared biological nature.
RESULTS
Patient information and CTC retrieval
The studied patient underwent a prostatectomy and 
then experienced biochemical relapse 1 year later. He 
was started on medical castration therapy. He progressed 
through castration therapy 3 years later. Multiple osseous 
metastases were detected at that time. He then underwent 
multiple hormonal maneuvers but developed hepatic 
metastases. He received multiple systemic therapies including 
abiraterone, docetaxel, and an experimental targeted therapy. 
Commercially-available genomic profiling of a biopsy from 
his hepatic metastasis was performed but did not identify any 
targetable mutations.
NanoVelcro Chip was used in conjunction with 
a laser capture microdissection (LCM) microscope to 
isolated the captured CTCs (Figure 1A and 1B) [18]. We 
isolated a total of 99 CTCs from 5 blood samples collected 
over 4 months. A previous verified multiplex PCR of 8 
housekeeping genes was performed to assess the integrity 
of the amplified DNA (Figure 1C) [22]. High-quality 
DNA samples suitable for WGS were obtained from 2 
CTCs captured in at the outset of our collections (A9 and 
A16) and 2 from a visit 4 months later (U15 and U17). 
Moderate-quality DNA samples suitable for WES were 
obtained from an additional 8 CTCs (S12, S13; U22, 
U23, U32; W6, W7, Y17). White blood cells (WBCs) and 
adjacent normal prostate tissue obtained from his archival 
prostatectomy specimen were used as controls. A time 
course of his clinical history with specimen collection is 
presented in Figure 1D and supplementary Figure S1.
Single-CTC WGS was performed with quality 
comparable to tissue sequencing
WGS was carried out with paired-end 100-bp reads 
and ~350 bp inserts on an Illumina platform. Mean depths of 
28–36X were achieved. All of the tumor and CTC sequencing 
runs had more than 95% genome coverage (95.6% to 99.6%) 
with more than 87% (87.6% to 91.5%) of the areas covered 
in sufficient depth (>10X) for calling variants with high 
confidence (Figure 2A and 2B; supplementary Table S1). GC 
content was compared between single CTCs and the WBC 
control to asses WGA quality. Correlation coefficients were 
all > 0.999, which indicated the absence of WGA associated 
bias (supplementary Table S2). Uniformity of coverage 
was assessed by Lorenz curves as proposed by a previous 
single cell sequencing study [24]. Our single-CTC WGS 
coverage uniformity was similar to the published date of the 
aforementioned study (Figure 2C). The single CTC coverage 
uniformity was also similar to that seen in WBC and primary 
tumor tissue WGS (supplementary Figure S2). Finally, the 
comparison of single nucleotide polymorphisms (SNPs) also 
showed that the total number and the distributions of SNPs in 
single-CTC samples were not different from the tumor tissues 
(Figure 2D and supplementary Table S3). In summary, all 
results were consistent with high-quality sequencing.
SSNV comparison between CTCs and 
tumor biopsies
SSNV profiles of CTCs to the primary and metastatic 
tissues were compared using the MuTect algorithm [25]. 
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Figure 1: Performing CTC WGS in a patient with lethal liver metastasis. A. Patient history and sampling time. B. Schematic 
workflow for our CTC WGS technology. (i) The NanoVelcro Chip consists of a cell-affinity substrate electrospun with PLGA nanofibers 
and an overlaid PDMS chaotic mixer. (ii) After determining CTCs based on their fluorescence (CD45-/CK+) and morphology, the LCM 
microscope was used to isolate single CTCs by laser dissection. (iii) Schematic illustration of WGA using multiple displacement amplification. 
(iv) Whole genome sequencing. C. Micrograph images recording the process of CTC isolation by LCM. (i) CTC identification; (ii) UV laser 
dissection; (iii) The CTC is removed from the substrate; (iv) isolated CTC was confirmed on the LCM cap. D. A gel electrophoresis figure 
showing good amplification and poor amplification WGA products.
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We anticipated that some genomic alterations would not 
be present in all clones given the underlying heterogeneity 
within the population of tumor cells [26]. As such, we first 
identified the founder SSNVs shared between the primary 
and metastatic tumors. These founder SSNVs were then 
used to assess the similarity between CTCs and tissues. 
Among the 802 founder SSNVs in primary and metastatic 
PCa cells, a median of 61 (range 43–74) mutations 
were identified by MuTect in each of the single-CTCs. 
However, with a manual review of founder mutation 
sites, a median of 157 mutations (range 125–177) were 
identified with supporting reads in the single-CTCs. The 
identified shared founder SSNVs increased when the size 
of the CTC pool increased. A total of 230 founder SSNVs 
(28.7%) had supporting reads discovered in any of the four 
CTCs, where 117 SSNVs were called by MuTect (Figure 
3A). To further evaluate the similarity between CTCs and 
tumor tissues, we identified clonal SSNVs from CTCs—
defined as SSNVs shared by more than three CTCs. 
These SSNVs were repeatedly detected in more than 
three single-cell sequencing runs and can be considered 
high confident mutations, as previously reported [20, 22]. 
We found that 86.0% (197/229) of these clonal SSNVs 
in CTCs had supporting reads discovered in either the 
primary or metastatic tissues, where 116 SSNVs (50.7%) 
were called by MuTect (Figure 3B).
To further examine the heterogeneity of the CTC 
mutational landscape, WES was performed on 8 of 
the CTCs with moderate quality DNA. Coverage of 
24.6–78.5% was achieved. To assess the probability of 
mutations in the single CTCs at each locus based on the 
sequencing reads, we derived the log odd (LOD) score 
using a Bayesian model adjusted by the allele drop out 
(ADO) rate (see detailed methods in the supplementary 
Figure 2: Sequencing quality assessments. A. The sequencing depth of each sample. B. The percentage of area covered. C. The 
Lorenz curves comparing the homogeneity of coverage of CTC-U17, and a published single-cell sequencing data. D. The SNP densities of 
CTCs and tumor tissues. Height of rectangles ranges from 0–1000/100 Kb, bin = 100 Kb. The rings from the inside out represent CTC-U17, 
CTC-U15, CTC-A9, CTC-A16, liver metastasis, and primary prostate tumor. The outermost ring represents the karyotype of the human 
genome reference sequence (hg19), with red areas being centromeres.
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Figure 3: The similarity of SNVs between CTCs and tumor tissue. A. The number of founder SSNVs (SNVs shared between 
primary and metastatic tumors) discovered when a different number of CTCs are involved in the analysis. The upper curve represents the 
number of shared SNVs identified by the presence of supporting reads. B. The origin of clonal SSNVs in CTCs. C. The exonic mutational 
landscape of this patient’s CTCs. Higher log odd (LOD) scores indicate more likely the CTC harboring the mutation. For the concern of 
visualization, we used base 10 log and truncated the maximum value to 1. Thus, LOD = 1 means the posterior probability of a mutant is 10 
times as big as the posterior probability of normal and LOD ≥ -5 means the likelihood of mutant is greater than normal (see Methods for 
details). The allele fractions of the primary and metastatic tumors are also plotted.
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information). A heatmap was constructed based on the 
LOD score of 13 exonic mutations that were detected 
either in at least two CTCs or at least one CTC and a 
tumor tissue sample. Additional exonic SSNVs were found 
shared between CTC and tumor tissues in the WES study, 
which were not detected in the CTC WGS (Figure 3C). To 
better evaluate if the clonal mutations are more frequently 
found in CTCs, we plotted the allele fractions of each 
exonic mutations in the primary and metastatic tumors. 
We observe that mutations in primary or metastasis 
with higher allele fractions, which are more clonal, are 
more frequently mutated in CTCs. These findings were 
confirmed using three additional methodologies. First, we 
compared our tumor tissues and CTCs with both WBC 
and normal adjacent prostate tissue instead of using a 
more general approach of comparing tumor tissue with 
one normal tissue source to identify SSNVs. Second, 
we performed WES on a separate batch of WBCs and 
confirmed that 99.1% (770/777) of the exonic SSNVs 
detected in our WGS were not germline SNPs. Third, we 
randomly selected SSNV loci for additional confirmation 
by Sanger sequencing. The majority (23/25, 92%) of them 
were confirmed (supplementary Table S4).
Structural variation (SV) comparison between 
CTCs and tumor biopsies
To examine the similarities in SVs, we utilized 
a two-step approach employing the CREST algorithm 
[27] to identify breakpoints and then performed manual 
checks of supporting reads in multiple samples. We found 
no rearrangements associated with ERG, ETS, or their 
reported fusion partners [28] in the CTCs or tumor tissues. 
Two SVs were shared among CTCs and both tissues, 
including an intrachromosomal SV in chromosome 3 
(Figure 4A and 4B) and a SV between chromosome 13 
and 15 (Figure 4C). The SV in chromosome 3 involves 
TMEM207, which has been associated with migration 
and invasiveness [29]. The breakpoints of these SVs are 
identical between cancer tissues and the CTCs.
Finally, we screened known tumor suppressors for 
possible functional SVs. We found complex SV profiles 
in PTEN, RB1 and BRCA2 in all our samples that were 
not detected in the WBCs and normal tissue controls 
(Figure 5). These SVs were mostly between 0.6 kb to 2 kb 
in size. The patterns varied widely between primary and 
metastasis as well as each of the CTCs.
Copy number variation (CNV) comparison 
between CTCs and tumor biopsies
CNVs represent important genomic alterations 
in PCa [30]. CNVs were assessed by the CASS and 
FREEC algorithms [31, 32]. No CNVs were identified 
in the primary tissue. This finding was confirmed by an 
array comparative genomic hybridization (aCGH) assay, 
suggesting that no founder CNVs were present in this 
patient (supplementary Figure S3)—a common finding 
in PCa patients [33]. In the liver metastasis sample, we 
observed some large segment amplifications, including 8q, 
which are also commonly reported in PCa [34]. Besides 
the small deletions near the ends of the chromosomes or 
close to the centromere, the single-CTC WGS data did 
not identify any prominent CNVs. The similarity between 
CTCs and tumor tissues by CNV analysis was limited due 
to the lack of founder CNVs. However, this result does 
demonstrate a highly homogeneous WGA process for our 
single CTCs (supplementary Figure S4).
DISCUSSION
PCa continues to be the most common cancer 
affecting men in the United States. Over 20,000 American 
men will die from this disease in 2015 [35]. The presence 
of evolving temporo-spatial heterogeneity in PCa has 
been recognized as an important biological problem with 
clinical impact [33, 36]. Tumor tissue analysis (typically 
from biopsy or resection) remains the most commonly 
employed means of studying metastatic PCa in patients. 
Bone is the most common site for PCa metastasis. Though 
possible to obtain, bone biopsies are invasive and often 
technically challenging. Moreover, it is difficult to obtain 
biopsy at a clinically optimal frequency (e.g. monthly) 
for patients with advanced disease. Given the pace of 
disease progression in certain patients, it may be necessary 
to have this dynamic range if we attempt to understand 
the evolving biology underlying the disease. As such, 
CTCs are an appealing alternative source of information 
if the underlying biology of the malignancy is reflected 
within them.
This study shows that it is possible to obtain high-
quality WGS data from individual CTCs following a 
microfluidic-based isolation approach. Specifically, 
we used a unique combination of technologies: the 
NanoVelcro chip for CTC capture, LCM for single-
CTC isolation, and an Illumina sequencer for WGS. Our 
methodology achieved WGS coverage of above 95% 
across the 4 single-CTCs. All quality assessments from 
the single-CTC WGS were comparable to that obtained 
from tissue sequencing. This made it possible to analyze 
SSNVs and SVs in CTCs and conduct a comparison with 
tumor tissue from a PCa patient.
Our high-level of coverage was attributed to the 
unique advantages of our combined methodology over 
other existing CTC isolation and sequencing technologies 
[19, 20]. First, highly efficient CTC enrichment was 
achieved by combining NanoVelcro substrates and a 
microfluidic chaotic mixer as described previously [37, 
38]. Second, using LCM, single-CTCs immobilized on the 
NanoVelcro substrates were visually distinguished from 
the surrounding WBCs and were manually and specifically 
isolated. Third, the negatively charged PLGA NanoVelcro 
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substrates prohibited non-specific adsorption of cell-free 
DNA, and decreased contamination by circulating DNA in 
the subsequent WGS [39]. The integrity of the CTC DNA 
was preserved by this streamlined protocol that allowed 
rapid processing from the initial CTC enrichment steps to 
WGA [18]. Instead of PCR-based amplification, multiple 
displacement amplification (MDA) was utilized to amplify 
CTC DNA in long fragments. This approach decreased the 
loss of unamplified segments. MDA is also the least biased 
approach that reduces false positive SSNVs [40]. Knowing 
that paraformaldehyde fixation compromises DNA quality, 
we intentionally avoided the use of paraformaldehyde for 
the CTCs to minimize interference during MDA [41]. 
An additional rigorous quality check was employed to 
select high-quality CTC samples by a multiplexed PCR 
based on 8 housekeeping genes. With these technological 
Figure 4: Shared SVs between CTCs and tumor tissues. A. Illustrative representations of the TMEM207 rearrangement. B. The 
breakpoint and supporting reads of the TMEM207 rearrangement in primary, metastatic tumors and CTCs (A9, U15 and U17). C. The 
breakpoint and supporting reads of a chr13-chr15 translocation in CTCs, indicating exactly the same rearrangement in primary, metastatic 
tumors and CTCs (A9, and U17).
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improvements, the quality of our WGS exceeded all 
previously published attempts to sequence CTCs.
The high level of coverage in our WGS enabled 
comparison of SSNVs in CTCs and tumor tissues. This 
created the opportunity to perform a comprehensive 
comparison of SSNVs at the whole genome level. 
Comparing 4 single CTCs with tumor tissues from the 
index patient, we found that 86% of the clonal SSNVs 
identified in the CTCs (Figure 3B) were shared with the 
primary or metastatic tumor tissues. This observation is 
supported by a recent work by Lohr et al., which revealed 
70% of the clonal SSNVs in CTCs can be traced back 
to tumor tissues using WES [20]. Due to the concern 
that some of the shared SSNVs were germline SNPs 
not detected in the control tissues, rigorous standards 
were applied for the identification of SSNVs. WGS was 
performed on both WBCs and the adjacent normal prostate 
tissue to increase the sensitivity of the germline SNP 
detection. Additional WES on a separate batch of WBCs 
confirmed that 99.7% of the exonic SSNVs detected in our 
WGS were not present in WBCs as germline SNPs. This 
demonstrates that a minimal level of germline SNPs was 
present and therefore could not confound our analyses. 
Further Sanger sequencing on randomly selected loci 
validated 92% of the SSNVs identified in our study.
There remained a concern that some of the shared 
mutations between CTCs and tissues were introduced 
during single-cell DNA amplification and sequencing. To 
avoid this error, the comparison of SSNV was based on 
WGS data obtained from the primary and metastatic tumor 
tissues. We identified a total of 802 founder SSNVs shared 
between the primary and metastatic tumors. Then we 
determined if these SSNVs were present in CTCs. In the 
literature, the established MDA-induced sequencing error 
rate is in the range of 10 − 5 [22, 23]. As such it is unlikely 
that a significant portion of these shared mutations 
(28.7%) were caused by WGA errors.
In this study, we identified 9 exonic SSNVs shared 
between CTCs and either of the tissues, (Figure 4C) as 
well as more than 200 somatic genomic SSNVs shared 
between CTCs and both of the tumor tissues. Compared 
to the report showing as many as 73% of SSNVs shared 
between primary tumor and metastasis via WES [20], we 
noted only a minor portion (28.7%) of tumor tissue SSNVs 
in the CTCs using WGS approach. This result was not 
unexpected considering the known heterogeneity in PCa 
as well as the clinical presentation of the analyzed patient. 
A high degree of intratumoral genomic heterogeneity 
in cancer has been shown by multiple-region exome 
sequencing on multiple clones obtained from a solid tumor 
[26]. This same approach in PCa also showed a small 
number (0–8) of exonic SSNVs shared between different 
regions of a primary tumor [42]. Several reports using 
aCGH and WGS approaches to analyze different PCa 
Figure 5: SVs in important tumor suppressor genes were shared between CTCs and tumor tissues. Heterogeneous SVs 
were found in important tumor suppressor genes, including BRCA2, PTEN and RB1. These SVs were mostly between 0.6 kb to 2 kb in size, 
and were not detected in the WBCs and normal tissue controls. The patterns varied widely between primary and metastasis as well as each 
of the CTCs.
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tumors also demonstrated this intra-tumoral heterogeneity 
[36, 43]. The report from Navin et al. further revealed 
a high-degree of heterogeneity at the cellular level by 
studying single cells from a dissociated tumor tissue [44]. 
The CTCs from our patient were obtained at a point in 
his natural history when he had both osseous and hepatic 
metastases. Overall, there should be a high degree of 
genomic heterogeneity at the intercellular, intra-tumoral, 
and inter-tumoral levels.
SVs, such as ETS rearrangements, constitute an 
important portion of founder mutations in PCa [45]. 
Acknowledging their importance in biology, we performed 
the first whole genome SV analysis on single CTCs. Our 
patient was not found to have an ETS fusion. However, we 
discovered two large segment rearrangement events shared 
between tumor tissues and CTCs (Figure 4). These SVs 
were undetected in WBCs and the normal tissue control. 
The presence of these shared rearrangements implies that 
they developed early in the course of disease evolution, 
which is consistent with the current understanding that 
some early rearrangements may be the drivers of PCa 
oncogenesis [28]. The SV and the SSNV analysis point 
toward a shared genetic origin for the CTCs and the 
metastatic lesion.
We also identified SVs involving important tumor 
suppressor genes, such as PTEN, in CTCs and tumor 
tissues (Figure 5). PTEN SVs are among the most common 
in PCa [46]. We observed extensive heterogeneity in 
both the CTCs and the tumor tissues. This observation 
suggested that these rearrangement events may have 
been acquired separately which is consistent with 
characterization of PTEN mutations as a late event in the 
evolution of PCa [47]. Before more powerful tools for SV 
detection are available, we point out that it may be difficult 
to identify which differences are meaningfully reflecting 
the heterogeneity of the disease. To address the growing 
interests in single-cell biology, new algorithms may be 
needed to identify SVs in single cells. We propose that 
that single-cell RNA sequencing may also be performed to 
cross validate the discovery of fusion products.
Similar to a previous study [20], we observed a 
trend (Figure 3A and 3C); the number of shared mutations 
discovered in the CTCs increased as we sequenced more 
CTCs. This would imply that at any given time point, 
multiple CTCs would be needed to better approximate the 
genomic content of the underlying disease (i.e. addressing 
spatial heterogeneity). Though a substantial amount 
of genomic information can be acquired from a limited 
number of CTCs, more CTCs would provide an even 
more comprehensive representation of the tumor genome. 
This is further complicated by the genetic evolution of the 
disease (i.e. temporal heterogeneity). To better address 
this issue, multiple CTCs would need to be captured at 
numerous time points. Also, Figure 4A shows that a large 
portion of shared mutations was found in CTCs as minor 
alleles with a small numbers of supporting reads. These 
mutations may have been underrepresented due to the 
preferential amplification of one allele during the WGA 
process. This suggests that increased sequencing depth 
may be needed to increase the sensitivity of the detection 
of mutations that present as minor alleles. In addition, 
circulating tumor DNA (ctDNA) may also provide an 
alternative source of materials for biological study [48–
50]. Without the need of amplification, ctDNA sequencing 
may serve as a complementary strategy to reduce the false 
positive calls in single-CTC sequencing.
Prior published CTC sequencing efforts have 
resulted in lower coverage making WGS identification 
of CNVs, SVs, and SSNVs very challenging. Our 
methodology makes the analysis of CTC genomes with 
adequate quality for the assessment of SSNVs and SVs 
possible. Future work will focus on the utilization of CTC 
genomic characterizations from serially collected samples 
to perform a real-time, dynamic monitoring of a patient’s 
cancer. Such a prospect is promising in diseases such as 
PCa, where tumor biopsies cannot be performed easily. 
Our single-CTC capture approach can also be modified 
to allow for the characterization of RNA instead of 
DNA. This will allow for the dynamic monitoring of the 
transcriptomes of metastatic castration-resistant PCa as 
well as in other cancers.
While the approach of performing multiple WGS 
studies on individual CTCs may seem impractical at this 
time, as sequencing technologies improve and as costs 
decline, this approach may be useful in understanding 
the dynamic evolution of heterogeneity in an underlying 
cancer. Genomic instability in cancer has been recognized 
as a potential barrier to personalized medicine in oncology 
given its relationship to therapeutic resistance. More 
recently, it has been hypothesized that this instability may 
result in larger generation of neoantigens increasing the 
benefit of immunotherapy [51, 52]. As such, this unique 
approach to dynamic characterization of heterogeneity 
may have clinical utility in the future.
In summary, our work demonstrates the feasibility 
of conducting WGS on single CTCs. This may provide 
a means to study cancer in real-time with simple serial 
phlebotomy as opposed to serial biopsy. Studies of this 
nature may provide valuable insights into the molecular 
mechanisms of disease progression.
MATERIALS AND METHODS
NanoVelcro chip for single CTCs isolation
We captured single CTCs for WGS using a 
NanoVelcro Chip composed of a nanofiber cell-affinity 
substrate and an overlaid chaotic mixer. This chip was used 
in conjunction with a laser capture microdissection (LCM) 
microscope to isolated the captured CTCs (Figure 1A and 
1B) [18]. To ensure sufficient DNA input for WGS from 
the individually isolated CTCs, we performed WGA using 
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multiple displacement amplification (MDA) on the DNA 
derived from single CTCs. A previous verified multiplex 
PCR of eight housekeeping genes was performed to assess 
the integrity of the amplified DNA (Figure 1C) [22]. Only 
high-quality WGA products were selected for library 
construction and WGS.
Patient and samples
Collection of blood and tissue samples and clinical 
information in this study was approved by the Institutional 
Review Board at Cedars-Sinai Medical Center (CSMC). 
Written consent was obtained from the patient described 
herein. Archival FFPE tissues, including primary tumor 
tissue, adjacent normal and liver metastasis tissues were 
obtained from the pathology core at CSMC. Blood was 
also collected for CTC isolation over a span of 4 months.
We isolated single CTCs for WGS using a 
NanoVelcro Chip composed of 1) a cell-affinity substrate 
coated with poly(lactic-co-glycolic acid) (PLGA)-
nanofibers and 2) an overlaid PDMS chaotic mixer. This 
chip was used in conjunction with a LCM microscope 
to isolated the captured CTCs [18]. In brief, PLGA-
nanofibers were electrospun onto a LCM-compatible 
substrate. These nanofibers were covalently functionalized 
with streptavidin to enable selective capture of CTCs 
labeled with biotinylated anti-EpCAM. This surface 
facilitates CTC capture using its unique topographical 
interactions between the nanostructured components (e.g. 
microvilli) on the CTC surfaces and the PLGA-nanofibers 
on the NanoVelcro Chip. The PDMS chaotic mixer 
introduces helical flow that further increases the contact 
frequency between CTCs and the substrate surface. After 
CTCs immobilized on the substrate, the CTC-bearing 
substrate was stained with FITC-labeled anti-cytokeratin 
(CK), a standard marker for CTCs, and TRITC-labeled 
anti-CD45, a standard WBC marker. CTCs were defined as 
CK+/CD45- cells whose morphology could be confirmed 
using bright field microscopy. Finally, LCM was utilized 
to collect single CTCs. The WBCs in the flow-through of 
NanoVelcro CTC Chips were also collected.
Single-CTC and tissue sequencing
Multiple displacement amplification was used to 
conduct WGA for individual CTCs. A multiplex PCR 
protocol was performed over 8 preselected housekeeping 
genes on different chromosomes for post-amplification 
quality assessment. Only samples with more than 6 
housekeeping genes detected were considered high-quality 
and were utilized for WGS. DNA from tumor specimens 
from the archival tissues underwent the same amplification 
process. Non-tumor DNA was extracted from WBCs. 
WGS was performed on the Illumina HiSeq 2000 platform 
with paired-end 100 bp runs. WGS was carried out with 
paired-end 100-bp reads and ~350 bp inserts. Additional 
8 CTCs with moderate quality were subjected to whole 
exome sequencing (WES). The DNA library was prepared 
using the TruSeq DNA kit (Illumina) followed by exome 
enrichment using the SeqCap EZ Human Exome library 
kit (v3.0, Roche).
We used the Homo sapiens reference genome 
sequence (hg19) and its annotation files (dbSNP v137) 
for WGS data analysis (Raw data available in GenBank, 
SRA121256). CNVs were assessed by CASS and FREEC 
[31, 32]. SSNVs were identified by MuTect 1.1.4 [25]. 
Founder SSNVs were identified as the SSNVs shared 
between the primary and metastatic tumors. Clonal 
SSNVs in the CTCs were defined as SNVs detected in 
at least 3 single CTCs [20, 53]. A modified Bayesian 
probabilistic model was utilized to assess the confidence 
of SSNV calls by considering ADO rates into the analysis. 
For the mutations repetitively observed in multiple WGS 
samples, algorithms including PolyPhen-2 were employed 
to predict their functional roles in disease progression 
[54]. Breakpoints of possible structural variations (SVs) 
were identified by CREST [27]. As CREST was not 
originally designed for our approach, supporting reads 
were verified manually for large segment rearrangements 
(see supplementary methods for detailed information).
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